Entera Bio Ltd. (ENTX) stock

ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/30

$3.11−0.11 (-3.42%)

Close on Nov 13, 2026Market cap $538.47MP/E –Yield –

Entera Bio r&d expenses

Research and development expenses are spending on new products and technology.

Entera Bio's R&D Expenses for the twelve months ending Sep 30, 2026 was $12.10M, up 120.4% year over year. For fiscal 2025 it was $6.00M, up 33.5% from the year before. The highest annual figure on record is $8.52M in fiscal 2018.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$6.00M	+33.5%
FY2024	Dec 31, 2024	$4.50M	-0.2%
FY2023	Dec 31, 2023	$4.51M	-22.9%
FY2022	Dec 31, 2022	$5.85M	-13.6%
FY2021	Dec 31, 2021	$6.77M	+6.1%
FY2020	Dec 31, 2020	$6.38M	-11.3%
FY2019	Dec 31, 2019	$7.20M	-15.5%
FY2018	Dec 31, 2018	$8.52M	+207.7%
FY2017	Dec 31, 2017	$2.77M	+4.5%
FY2016	Dec 31, 2016	$2.65M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$4.93M	+199.8%
Q2 FY2026	Jun 30, 2026	$3.20M	+110.6%
Q1 FY2026	Mar 31, 2026	$2.25M	+100.4%
Q4 FY2025	Dec 31, 2025	$1.72M	+43.0%
Q3 FY2025	Sep 30, 2025	$1.64M	+11.2%
Q2 FY2025	Jun 30, 2025	$1.52M	+40.0%
Q1 FY2025	Mar 31, 2025	$1.12M	+52.8%
Q4 FY2024	Dec 31, 2024	$1.20M	+20.1%
Q3 FY2024	Sep 30, 2024	$1.48M	+7.8%
Q2 FY2024	Jun 30, 2024	$1.09M	-10.2%
Q1 FY2024	Mar 31, 2024	$735.00K	-21.1%
Q4 FY2023	Dec 31, 2023	$1.00M	-26.0%
Q3 FY2023	Sep 30, 2023	$1.37M	-3.0%
Q2 FY2023	Jun 30, 2023	$1.21M	-13.3%
Q1 FY2023	Mar 31, 2023	$931.00K	-44.9%
Q4 FY2022	Dec 31, 2022	$1.35M	-49.0%
Q3 FY2022	Sep 30, 2022	$1.41M	-20.2%
Q2 FY2022	Jun 30, 2022	$1.39M	+13.6%
Q1 FY2022	Mar 31, 2022	$1.69M	+50.4%
Q4 FY2021	Dec 31, 2021	$2.65M	+31.7%
Q3 FY2021	Sep 30, 2021	$1.77M	+25.3%
Q2 FY2021	Jun 30, 2021	$1.23M	–
Q1 FY2021	Mar 31, 2021	$1.12M	–
Q2 FY2020	Jun 30, 2020	$2.01M	–
Q2 FY2019	Jun 30, 2019	$1.41M	–